Suggested remit - To appraise the clinical and cost effectiveness of anakinra within its marketing authorisation for treating Still's disease
 
Status In progress
Process STA 2018
ID number 1463

Provisional Schedule

Committee meeting: 1 08 April 2020
Expected publication 26 June 2020
The company requested additional time to allow them to gather more evidence to provide a robust submission to NICE. NICE have agreed to this and the new deadline for submissions is expected to be mid-October 2019. 10 September 2020

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Consultees

Companies sponsors Swedish Orphan Biovitrum (anakinra)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Royal College of Physicians

Commentators

Comparator companies Novartis (ciclosporin, mycophenolate, canakinumab) (confidentiality agreement signed, participating)
  Accord Healthcare (mycophenolate, methotrexate) (confidentiality agreement not signed, not participating)
  Baxter Healthcare (cyclophosphamide) confidentiality agreement not signed, not participating)
  Bristol Laboratories (hydroxychloroquine) confidentiality agreement not signed, not participating)
  Concordia International (methotrexate) confidentiality agreement not signed, not participating)
  Creo Pharma (hydroxychloroquine) confidentiality agreement not signed, not participating)
  Genesis Pharmaceuticals (sulfasalazine confidentiality agreement not signed, not participating)
  Hospira UK (methotrexate) confidentiality agreement not signed, not participating)
  medac UK (leflunomide, methotrexate) confidentiality agreement not signed, not participating)
  Mylan (ciclosporin, leflunomide) confidentiality agreement not signed, not participating)
  Nordic Pharma (methotrexate) confidentiality agreement not signed, not participating)
  Orion Pharma (methotrexate) confidentiality agreement not signed, not participating)
  Pfizer (sulfasalazine, methotrexate) confidentiality agreement not signed, not participating)
  Roche (tocilizumab, mycophenolate) confidentiality agreement not signed, not participating)
  Rosemont Pharmaceuticals (sulfasalazine, methotrexate) confidentiality agreement not signed, not participating)
  Sandoz (cyclophosphamide, methotrexate) confidentiality agreement not signed, not participating)
  Sanofi (leflunomide) confidentiality agreement not signed, not participating)
  Teva UK (ciclosporin, mycophenolate, methotrexate, hydroxychloroquine) confidentiality agreement not signed, not participating)
  Therakind (methotrexate) confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
07 March 2019 Invitation to participate
07 March 2019 In progress, Appraisal start
26 September 2018 - 24 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance